Pharmaceutical innovation partner CPI has created Digital Architecture, a step-by-step strategic guide designed to enable pharmaceutical companies to digitalise the manufacturing process.
The organisation's Digital Architecture was crafted in collaboration with top industry players, including AstraZeneca, GSK, Siemens Atos, AWS and Capgemini, and will allow the industry to reduce its carbon footprint by up to 20%.
It will also provide a framework for drug manufacturers to smoothly integrate digital technologies, overcome data silos and enable real-time release.
The guidelines will speed up product release times, while also driving the industry towards autonomy
Notably, CPI states that the guidelines will speed up product release times, while also driving the industry towards autonomy.
As digitalisation becomes a strong priority for all manufacturers, it is having a profound impact on pharmaceutical processes, driving their decarbonisation and operational efficiency.
For pharma companies striving to implement an autonomous pharmaceutical manufacturing strategy, the challenges of integrating legacy infrastructure, managing vast amounts of siloed data and justifying capital investment have long been barriers to progress.
By providing the Digital Architecture, CPI hopes to provide companies with a structured approach to overcoming such challenges, making digitalisation a reality.
It will also allow companies to incrementally integrate their information technology (IT) and operational technology (OT) infrastructure, avoiding the risks associated with a full-scale digital overhaul.
Francis O’Doherty, Director, Operations IT at AstraZeneca, said: “AstraZeneca has successfully leveraged the work of this CPI collaboration to define our Autonomous Manufacturing strategy, which has supported our vision of implementing industry-leading pharmaceutical manufacturing and accelerated the development of our future ready IT architecture,"
“A technology agnostic digital architecture empowers us to choose the right solutions for our enterprise, ensuring flexibility and adaptability. Together, we are pioneering a transformative journey towards a digital-first and sustainable future, where AI-driven automation is augmented with human insights and oversight.”
“The pharmaceutical industry stands at a crossroads," added Dave Tudor, Managing Director of Pharma, HealthTech and Quality at CPI. "Companies must embrace digitalisation to stay competitive, but the complexity of integrating digital technologies has been a significant challenge.
“CPI’s Digital Architecture removes these barriers, offering a structured, technology-agnostic roadmap that allows companies to scale digital solutions efficiently. Our collaboration with global leaders ensures that this solution is practical, actionable, and aligned with the industry's future needs.”